maraviroc

Maraviroc (UK-427857, Selzentry) belongs to small molecule drugs and is a C-C chemokine receptor 5 antagonist with oral activity and selectivity. This compound is used for the treatment of HIV-1 infection and has also shown anti-inflammatory, neuroprotective, and potential antitumor synergistic effects in research.

Maraviroc-D6 is the deuterated form of Maraviroc (T6016). Maraviroc ( T6016) (UK-427857) acts as a selective CCR5 antagonist and exhibits inhibitory activity against HIV.

Maraviroc-D6 (Standard) is a reference standard of Maraviroc-D6 intended for quantitative analysis, quality control, and related biochemical research applications. Maraviroc-d6 is the deuterated form of Maraviroc. Maraviroc (UK-427857) acts as a selective CCR5 antagonist and exhibits inhibitory activity against HIV.

HGS101 is a fully humanized CCR5 monoclonal antibody that exhibits high affinity for CCR5. It binds to the second extracellular loop (ECL-2) and functions as a signaling antagonist. HGS101 restores the inhibitory effect of Maraviroc in Maraviroc-resistant HIV-1 infected PBMCs. In an uninfected simian immunodeficiency virus model of rhesus monkeys, HGS101 shows anti-HIV activity by inhibiting CCR5 signaling.

HGS004 is a humanized IgG4 monoclonal antibody inhibitor targeting CCR5. It exhibits potent antiviral activity against various CCR5-tropic HIV-1 strains, including those resistant to other treatments (such as Maraviroc-resistant strains). HGS004 is applicable for research in HIV-1 infection.